Literature DB >> 9136477

Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial.

K A Schulman1, M Buxton, H Glick, M Sculpher, G Guzman, J Kong, M Backhouse, J Mauskopf, L Bell, J M Eisenberg.   

Abstract

We present the prospective economic evaluation that served as a secondary endpoint for the FIRST study, a randomized international multicenter trial of patients with severe congestive heart failure. Although the clinical results of this study were disappointing, we demonstrated the feasibility of incorporating prospective economic evaluation in phase III clinical trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9136477     DOI: 10.1017/s0266462300010989

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

1.  Randomized controlled trial and economic evaluation.

Authors:  S Jain; N K Arora
Journal:  Indian J Pediatr       Date:  2000-05       Impact factor: 1.967

Review 2.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.

Authors:  Isao Mitani; Diwakar Jain; Tammy M Joska; Barbara Burtness; Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

Review 5.  Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.

Authors:  Simon Dixon; Emma McKeen; Margaret Tabberer; Suzy Paisley
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.